Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Sidney Street who wrote (10081)	5/19/2007 12:48:36 AM
From: Iamarangerboy	Read Replies (1) \| Respond to of 10280

have a bit of confusion regarding the depth of the sell-off even if the distinction between X and albuterol were no longer recognized by medicare. firstly, is this correct...... "Under the old codes, Medicare listed payment-allowance limits of 92 cents to $1.54 per unit dose for Xopenex, compared with 71 cents to 81 cents per unit dose of albuterol. In a recent quarterly update to the CMS web site, these codes are listed as discontinued as of July 1." does this mean that in the worse scenario, X will be treated as albuterol with a 71-81 cent reimbursement per unit dose? That is a bit less than 1/2. I would have thought the cuts to be more draconian than that to justify the sell-off. Especially considering the relatively low percentage of MC for X secondly, if those are truly the cuts, then would not X capture a much greater share of the overall market... what doc would order albuterol when he could order X for the same price? Makes no medical sense that X does not effectively capture the entire market. thirdly, X goes off patent in 2-3 years, as best I understand. How does all this justify such a drop. Anyone with insight please advise.... thanks